+44 20 3868 9735
The aim of this study is to determine the feasibility of nivolumab as maintenance therapy after first-line chemotherapy with carboplatin plus nab-paclitaxel in non-small-cell lung cancer. Since we cannot change the dose of nivolumab, we will investigate the recommended doses and cycles of pretreatment chemotherapy with carboplatin plus nab-paclitaxel that affect maintenance therapy. The primary endpoint is incidence of any grade ≥ 3 adverse events during the first 12 weeks of nivolumab treatment. Twelve patients are required in this study.